Discontinued — last reported Q4 '24
Financing
Proceeds From Issuance Of Subsidiary Common Shares Net
Roivant Sciences Proceeds From Issuance Of Subsidiary Common Shares Net increased by 89.0% to $112.78M in Q1 2025 compared to the prior quarter. Year-over-year, this metric grew by 89.0%, from $59.68M to $112.78M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ4 2020
Last reportedQ4 2024May 29, 2025
How to read this metric
Higher proceeds indicate strong market interest in the subsidiary's specific pipeline or technology, providing non-dilutive capital to the parent.
Detailed definition
Cash received by the parent company from the issuance of equity shares by its consolidated subsidiaries to third-party i...
Peer comparison
Specific to holding companies or conglomerates with multiple distinct business units.
Metric ID:
financing_proceeds_from_issuance_of_subsidiary_common_sh_391421Historical Data
11 periods
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $16.93M | $16.93M | $16.93M | $16.93M | $59.68M | $59.68M | $59.68M | $59.68M | $112.78M |
| QoQ Change | — | — | — | +0.0% | +0.0% | +0.0% | +252.5% | +0.0% | +0.0% | +0.0% | +89.0% |
| YoY Change | — | — | — | — | — | — | +252.5% | +252.5% | +252.5% | +252.5% | +89.0% |
Range$0.00 – $112.78M
Avg YoY Growth+219.8%
Median YoY Growth+252.5%
Current Streak8+ quarters growth
Proceeds From Issuance Of Subsidiary Common Shares Net at Other Companies
Frequently Asked Questions
- What is Roivant Sciences's proceeds from issuance of subsidiary common shares net?
- Roivant Sciences (ROIV) reported proceeds from issuance of subsidiary common shares net of $112.78M in Q1 2025.
- How has Roivant Sciences's proceeds from issuance of subsidiary common shares net changed year-over-year?
- Roivant Sciences's proceeds from issuance of subsidiary common shares net increased by 89.0% year-over-year, from $59.68M to $112.78M.
- What does proceeds from issuance of subsidiary common shares net mean?
- Cash raised by selling shares in a subsidiary company.